APAC Healthcare Weekly (Oct 4) – Hengrui, Hansoh, Chugai Pharma, Daiichi Sankyo, Otsuka, Sun Pharma
Hengrui stuck $2.6B outlicensing deal with Novo. EC revoked EU marketing authorization of Hansoh’s aumolertinib. Otsuka initiates NDA submission to...
97 Views
Primer: Ascletis Pharma (1672 HK) - May 2026
Ascletis is undergoing a critical strategic pivot from its legacy Hepatitis C (HCV) franchise, which has seen revenues collapse, to a high-risk,...
112 Views
APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review. InSilico initiates rentosertib Phase 3 trial in IPF. Samsung Biologics...
96 Views
APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma
CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...
103 Views
Ascletis Pharma (1672 HK): Pipeline Not Appealing Enough to Make the Placement Attractive
Ascletis Pharmais placing ~69M shares at the price of HK$12.18 per share to raise HK$835M to fund global Phase 3 trials of small molecule oral GLP...
154 Views